Because autoantibodies appear early in the course of disease, they can be used to establish disease-specific signatures to aid in early detection. Predictive signatures can be established to identify a disease state, sometimes before the patient begins to experience symptoms.
Autoantibody signatures can also play an important role in ensuring patients receive the right treatments. Development of companion diagnostics (CDx) helps safeguard patients by ensuring only those who will benefit from a drug will be treated with it.
Having the ability to interrogate many autoantibody targets in a single assay can help accelerate the identification and validation of signatures with high predictive value.